CANNABIS
THC/CBD oromucosal spray is not better than placebo for diabetic neuropathy over 12 weeks
Diabetes Care. 2010 ;33(1):128-130. http://dx.doi.org/10.2337/dc09-102930 patients with chronic painful diabetic peripheral neuropathy were randomized to receive Sativex (tetrahydrocannabinol 27 mg/mL and cannabidiol 25 mg/mL) or placebo, titrated over 2 weeks and maintained for 10 weeks. The purpose of this study was to determine if Sativex treatment results in better Neuropathic Pain Scale (NPS), total pain score (TPS), McGill Pain and QOL, SF-36 Health Survey, and EuroQOL scores compared to placebo. Results indicate that Sativex did not significantly improve scores for any outcome measure compared to placebo, and 6 of 30 patients withdrew due to adverse effects. Patients with depression had significantly higher baseline pain and pain improvements compared to non-depressed patients, regardless of treatment.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
